Topiramate Dosing for Cravings
For substance use cravings (alcohol, cocaine, amphetamines), initiate topiramate at 50 mg daily and titrate by 50 mg weekly to a target dose of 200-300 mg/day, divided into twice-daily dosing, over 6-8 weeks.
Dosing Algorithm by Indication
For Alcohol Use Disorder Cravings
The most robust evidence supports topiramate for alcohol cravings. Start at 25-50 mg daily and escalate by 25-50 mg weekly to reach 200-300 mg/day 1, 2. The landmark trial by Johnson et al. demonstrated significant efficacy at up to 300 mg/day, with participants showing 2.88 fewer drinks per day and 27.6% fewer heavy drinking days compared to placebo 2. A comparative trial found topiramate at a mean dose of 200 mg/day superior to naltrexone 50 mg/day for reducing alcohol intake and cravings 3.
Titration schedule for alcohol cravings:
- Week 1: 25-50 mg daily
- Week 2: 50-75 mg daily
- Week 3: 75-100 mg daily
- Week 4: 100-150 mg daily
- Week 5: 150-200 mg daily
- Week 6-8: 200-300 mg daily (target dose)
For Cocaine Cravings
Target 300 mg/day using the same escalation schedule 1. The randomized controlled trial by Kampman et al. showed topiramate 300 mg/day significantly increased cocaine nonuse days (13.3% vs 5.3% for placebo) and reduced craving during weeks 6-12 of treatment 1. The medication was particularly effective at reducing the reinforcing effects and monetary value of higher cocaine doses 4.
For Amphetamine/Methamphetamine Cravings
Target 200 mg/day 5. Start at 50 mg daily and gradually increase to 200 mg over 4-6 weeks. While evidence is more limited, a 2023 randomized trial demonstrated significant reduction in drug use temptation at weeks 8,10, and 12 at this dose 5.
Critical Dosing Considerations
Slow titration is essential to minimize cognitive and psychiatric side effects, which are the primary reasons for discontinuation. Rapid escalation increases dropout rates substantially 6, 7.
Twice-daily dosing is recommended once doses exceed 100 mg/day to improve tolerability and maintain steady plasma levels throughout the day.
Duration of treatment: Maintain the target dose for at least 12 weeks to assess efficacy, as craving reduction becomes statistically significant after 6-8 weeks of treatment 5, 1.
When to Discontinue or Adjust
- If no reduction in cravings after 12 weeks at target dose, discontinue treatment
- Taper when stopping: Reduce by 50-100 mg weekly to prevent seizure risk
- If intolerable side effects occur, reduce to the highest tolerated dose rather than discontinuing abruptly
Monitoring Requirements
- Baseline: Serum bicarbonate, creatinine, pregnancy test (if applicable)
- Ongoing: Monthly serum bicarbonate (risk of metabolic acidosis), pregnancy tests monthly for women of childbearing potential
- Monitor for cognitive impairment, word-finding difficulties, paresthesias, and mood changes
Common Pitfalls to Avoid
Do not use topiramate in pregnancy - it is highly teratogenic with known risk of orofacial clefts. Mandatory contraception is required 8.
Do not combine with carbonic anhydrase inhibitors - increases risk of metabolic acidosis and nephrolithiasis 9, 7.
Do not use in patients with history of kidney stones without careful risk-benefit assessment, as topiramate increases stone formation risk through carbonic anhydrase inhibition 9.
Avoid in patients with untreated glaucoma - topiramate can precipitate acute angle-closure glaucoma 7.
Context: Off-Label Use
Note that topiramate monotherapy is not FDA-approved for substance use disorders - this is off-label prescribing 9. The FDA approval is only for epilepsy, migraine prophylaxis, and weight loss (in combination with phentermine) 9, 10. However, prospective randomized controlled trials support its efficacy for alcohol and cocaine cravings 1, 2, making this a reasonable off-label application when other treatments have failed or are contraindicated.